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Tremendous progress has been made in the past two
decades in molecular genetics of heritable skin
diseases, and pathogenic mutations have been identi-
fied in as many as 500 distinct human genes. This
progress has resulted in improved diagnosis with
prognostic implications, has refined genetic counsel-
ing, and has formed the basis for prenatal and
presymptomatic testing and preimplantation genetic
diagnosis. However, there has been relatively little
progress in developing effective and specific treat-
ments for these often devastating diseases. However,
very recently, a number of novel molecular strategies,
including gene therapy, cell-based approaches, and
protein replacement therapy, have been explored for
the treatment of these conditions. This overview will
focus on the prototypic heritable blistering disorders,
epidermolysis bullosa, and related keratinopathies, in
which significant progress has been made recently
toward treatment, and it will illustrate how some of
the translational research therapies have already
entered the clinical arena.
Journal of Investigative Dermatology (2012) 132, 820–828; doi:10.1038/
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THE CLINICAL SPECTRUM OF GENODERMATOSES
Heritable skin disorders represent a group of conditions in
which the cutaneous findings can be relatively minor at one
end of the spectrum, being primarily of cosmetic concern and
limited to the skin, hair, and/or nails. In contrast, at the other
end of the spectrum, the cutaneous manifestations—often as
part of multisystem pathology—can cause significant mor-
bidity and untimely demise of affected individuals. Heritable
skin diseases can present a diagnostic challenge to practicing
dermatologists for several reasons (Pulkkinen et al., 2002).
First, many of these conditions are relatively rare, and
physicians may not be aware of the nuances and salient
diagnostic features of the clinical presentations. This difficulty
has been compounded by historically complex classification
schemes, often riddled with eponyms. Second, in many of
these conditions, there is considerable intra- and inter-
familial heterogeneity, which, when combined with incom-
plete penetrance and/or late-onset of manifestations, can
obscure timely diagnosis. Third, in many of these diseases,
the diagnosis is primarily made on the basis of clinical
presentation, and histopathological and ultrastructural find-
ings are often nonspecific. However, over the past two
decades, with the advent of molecular genetics in general
and completion of the human genome project in particular,
molecular diagnostics have become a standard for confirma-
tion of diagnoses, with potential for earlier detection. In fact,
as many as 500 different genes are now known to harbor
mutations in a manner that the genetic lesions explain the
cutaneous manifestations in these conditions (Feramisco
et al., 2009).
Examination of the mutation databases in different
heritable skin diseases reveals both obvious candidate genes
and a number of surprises. An example of a clearly
identifiable candidate gene is epidermolysis bullosa (EB),
constituting a group of heritable blistering disorders manifest-
ing with fragility of skin and mucous membranes (Fine et al.,
2008). In fact, two decades ago, when very little was known
of the molecular pathology of this disorder, we made a
prediction that mutations in the genes encoding the protein
components of the structural attachment complexes at the
epidermal–dermal basement membrane zone could explain
the fragility of skin in different forms of EB (Uitto and
Christiano, 1992). This prediction has since been proven
correct by demonstration of a number of mutations in as
many as 15 distinct genes encoding proteins necessary for the
physiologic integrity of the skin (Uitto et al., 2010).
In contrast to the obvious candidate genes, many of the
recently discovered genes with mutations in heritable skin
disorders have turned out to be surprisingly unpredictable,
and their role in skin biology in many cases was not
recognized before the identification of specific mutations.
An example of such a circumstance is pseudoxanthoma
elasticum, an ectopic mineralization disorder, which has
been shown to result from mutations in the ABCC6 gene that
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is expressed primarily in the liver and kidneys, and at very
low levels, if at all, in affected tissues, including the skin. The
ABCC6 gene encodes a transmembrane efflux transporter
protein, and it has been postulated that as a result of loss-of-
function mutations there is an absence of physiologically
circulating antimineralization factors, which allows ectopic
calcification of the peripheral connective tissues to ensue
(Uitto et al., 2011).
Apart from progress in understanding the molecular basis
of different genodermatoses, until recently, there has been
little progress in developing effective and specific treatment
strategies for these, mostly intractable, disorders. However,
identification of specific mutations in candidate genes and
elucidation of the consequences of such mutations at mRNA
and protein levels have provided a basis for the develop-
ment of novel therapeutic approaches, taking advantage of
progress in molecular and cell biology in general. This
overview will highlight selected genodermatoses, with focus
on EB and related blistering disorders, in which significant
progress has been made toward treatment, and it will
illustrate how several of these interventional modalities have
recently entered the realm of clinical trials (Uitto et al., 2010).
PRECLINICAL MODEL SYSTEMS
A number of model systems have been developed to examine
the pathomechanistic consequences of mutations in heritable
skin diseases, and many of these systems are also being used
for the development of molecular therapies. Especially
valuable toward understanding disease mechanisms has been
the development of transgenic animal models that recapitu-
late the clinical features observed in patients; these geneti-
cally modified animals have a major role in advancing our
understanding of mechanisms of different forms of EB
(Bruckner-Tuderman et al., 2010; Natsuga et al., 2010).
Besides providing direct evidence for the structural role
of many of the basement membrane zone adhesion
molecules, the development of transgenic mice with EB
phenotypes has provided novel information on the complex
secondary effects mediated by signaling pathways and other
systems that modify the EB phenotypes. In addition to
transgenic animals, EB phenotypes have been observed in a
number of animal species—both domestic and wild—as a
result of naturally occurring mutations (Jiang and Uitto,
2005; Bruckner-Tuderman et al., 2010). In many cases, the
suitability of these animal models for preclinical testing
of gene-, protein-, and cell-based molecular therapies has
been documented.
Although conventionally mice have provided the preferred
platform as a model for human diseases, often with
remarkable similarity to the human phenotype both at the
genetic, gross morphological, histopathological, and ultra-
structural levels, mouse systems can also have limitations.
These include their relatively long developmental lifespan
and the time it takes to develop a knockout mouse. Moreover,
in some cases, development of the knockout mouse as a
model of the corresponding human disease has turned out not
to be feasible because of the absence of the corresponding
gene in the mouse genome, or because the mutations in the
mouse gene result in embryonic lethality (Li et al., 2007;
Sercu et al., 2007). Furthermore, quite frequently, ablation of
a mouse gene fails to result in a detectable phenotype. Such
limitations, together with cost, have prompted a search for
alternative model systems to study heritable skin diseases.
One of the alternate model systems uses zebrafish (Danio
rerio), a small freshwater fish, which can be easily maintained
in the laboratory setting (Lieschke and Currie, 2007).
Zebrafish embryos develop and mature rapidly; therefore,
the development of organs, including skin, is largely
completed by 5–6 days after fertilization (Li et al., 2011).
Specifically, at 6 days after fertilization, the epidermis is
composed of two cell layers clearly separated from the
underlying connective tissue stroma by a basement mem-
brane that includes hemidesmosomal structures (Sonawane
et al., 2005). Examination of the developing zebrafish skin by
scanning electron microscopy reveals well-demarcated ker-
atinocytes, with the surface contour containing microridges
that are well organized by 6 days after fertilization. In
addition, zebrafish epidermis and the dermal–epidermal
basement membrane have characteristic landmark features,
with corresponding gene expression. Zebrafish have therefore
been suggested to serve as a suitable model system to study
heritable skin diseases (Li et al., 2011).
In addition to in vivo systems, cell cultures, including
keratinocytes and fibroblasts, provide experimental systems
to study the consequences of gene mutations. These cells can
be examined for phenotypic consequences, such as migration
and proliferation anomalies, as well as for changes in their
gene expression profiles. The mutant cells can also be
incorporated into artificial skin–equivalent systems ex vivo
with perturbations in the morphology and functionality of
skin layers, such as the stratum corneum and its barrier
function. Finally, treatment of cultured cells by corrective
pharmacological means, gene replacement approaches, or
manipulation of the degree of differentiation has advanced
our understanding of the diseases and has provided a
platform to develop novel treatments. Especially intriguing
are recent observations that cells, such as dermal fibroblasts,
can be converted to induced pluripotent stem cells (iPSCs),
with subsequent differentiation to essentially any cell type in
the body. This technology has the potential to develop
unprecedented approaches for patient-specific regenerative
medicine for heritable skin disorders.
MOLECULAR THERAPIES FOR EPIDERMOLYSIS BULLOSA
All forms of dystrophic epidermolysis bullosa (DEB) result
from mutations in the COL7A1 gene that encodes the
anchoring fibril protein, type VII collagen, which is normally
synthesized and secreted by both keratinocytes and fibro-
blasts (Stanley et al., 1985; Chen et al., 1994). In recessive
forms of DEB (RDEB), the pathogenic mutations typically lead
to reduced expression of type VII collagen (Christiano and
Uitto, 1996; Aumailley et al., 2006; Chung and Uitto, 2010).
Therefore, the therapeutic goal in RDEB is to increase type VII
collagen expression at the dermal–epidermal junction (DEJ) to
enable the skin to withstand trauma-induced blistering. To
achieve this goal, various strategies are being pursued using
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gene-, cell-, protein-, and drug-based approaches (Uitto
et al., 2010). However, reported clinical trials in patients with
RDEB have thus far been limited to cell therapy, either
involving intradermal injections of allogeneic fibroblasts,
which are derived from unrelated adult or neonatal donors,
or bone marrow–derived stem cell therapy.
Allogeneic fibroblast cell therapy for RDEB
In 2008, we reported a clinical trial in which single
intradermal injections of allogeneic fibroblasts were assessed
in five individuals with RDEB (Wong et al., 2008). In skin
biopsies from some individuals, fibroblast injection led to an
increase in type VII collagen expression, which was sustained
for several months. Injection of male fibroblasts into a female
patient, which allowed tracking of cells with a Y-chromo-
some probe, indicated that the donor fibroblasts were
undetectable 2 weeks after injection; yet, there was no
clinical evidence of inflammation, and the clinicopathologi-
cal benefits were sustained for several months (Wong et al.,
2008). Given the prolonged increase in type VII collagen
following allogeneic fibroblast injection, a key question has
been whether the new collagen at the DEJ is derived directly
from donor cells (‘‘direct release’’) or indirectly through
enhanced synthesis of mutant type VII collagen by the
recipient’s own keratinocytes and/or fibroblasts (‘‘indirect
release’’).
In support of the ‘‘direct release’’ theory, injection of
COL7A1 gene–corrected human RDEB fibroblasts or normal
control human fibroblasts (at sufficient cell density) into
immune-deficient mice was shown previously to lead to the
deposition of new human type VII collagen at the DEJ
(Woodley et al., 2003). Moreover, injection of normal human
fibroblasts into Col7a1 hypomorphic mice generated new
human type VII collagen at the mouse DEJ (Fritsch et al.,
2008; Kern et al., 2009). Favoring the direct release of type
VII collagen from fibroblasts were also the following
observations: (1) mutant fibroblasts did not exert any
paracrine effect (in murine studies); (2) following fibroblast
injection there was no upregulation of cytokines or growth
factors known to increase type VII collagen expression; and
(3) species-specific antibodies to type VII collagen showed
that human type VII collagen was present at the mouse DEJ
following injections of human fibroblasts (Kern et al., 2009).
In contrast, data consistent with ‘‘indirect release’’ stemmed
from observations that allogeneic fibroblast injection was
associated with (1) increased type VII collagen expression
within basal keratinocytes (in humans), (2) an absence of
mature anchoring fibrils following treatment, (3) increased
expression of recipient patient–specific mutant COL7A1
alleles at the mRNA level, (4) a greater increase in type VII
collagen at the DEJ in patients who expressed more type VII
collagen at baseline and who therefore had an enhanced
capacity to increase synthesis of their own mutant type VII
collagen, and (5) some increased expression of type VII
collagen following the irritant stimulus of saline injection
(Wong et al., 2008; Nagy et al., 2011). Moreover, recent
studies in one patient with recessive DEB identified heparin-
binding EGF-like growth factor as a novel putative growth
factor induced by fibroblast injections with the capacity to
increase type VII collagen expression (predominately from
the patient’s keratinocytes and therefore from mutant alleles)
(Nagy et al., 2011; Uitto, 2011a) (Figure 1). Heparin-binding
EGF-like growth factor has not previously been known to
influence type VII collagen expression; however, exposure of
patient and control keratinocytes and fibroblasts led to
increased COL7A1 gene expression with evidence of
increased AP1 transcription factor, probably accounting for
the enhanced type VII collagen expression (Nagy et al.,
2011).
With respect to wound healing in RDEB, however, one
randomized, double-blind study has shown no differences in
the extent or rate of reepithelialization of chronic erosions
following injections of fibroblasts or saline, although other
studies assessing the impact of allogeneic fibroblasts in
wound healing are ongoing (Venugopal et al., 2010; Yan and
Murrell, 2010; John A. McGrath, unpublished data). One
interesting observation has been that in the preinjection
monitoring of wounds in recessive DEB, many wounds,
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Figure 1. Postulated mechanism by which fibroblast therapy may ameliorate the blistering tendency in recessive dystrophic epidermolysis bullosa (RDEB).
(a) In normal skin, keratinocytes synthesize type VII collagen molecules (red), which assemble into anchoring fibrils. These fibrils entrap the interstitial
collagen fibers in the dermis, securing the stable association at the dermal–epidermal junction. (b) In some patients with RDEB, there are only a few rudimentary
anchoring fibrils, allowing formation of blisters below the lamina densa as a result of minor trauma. (c) Allogeneic fibroblasts injected directly into the
dermis elicit a subclinical immune reaction that leads to synthesis of heparin-binding EGF-like growth factor (HB-EGF), which upregulates the synthesis and
assembly of the patient’s own mutated type VII collagen. The increase in the rudimentary anchoring fibrils, which are partially functional, stabilizes the
association of epidermis to the underlying dermis and ameliorates the blistering tendency (adapted from Uitto, 2011a).
822 Journal of Investigative Dermatology (2012), Volume 132
J Uitto et al.
Heritable Skin Disorders
perhaps somewhat surprisingly, often show spontaneous
healing as well as breakdown with change in the shape and
size of eroded areas. Notably, within a particular area, the
healing of older wounds is often compounded by the
appearance of adjacent newer wounds (John A. McGrath
and Gabriela Petrof, unpublished data). It is evident that
careful selection and monitoring of wounds during clinical
trials of fibroblast cell therapy in RDEB is important in
determining whether an approach has clinical utility or
whether alternative cell therapy or other therapeutic mod-
alities might represent a better intervention. For now, the data
and cumulative clinical experience indicate that for a
subgroup of individuals with RDEB, notably those with
mild-to-moderate disease severity and some baseline expres-
sion of type VII collagen at the DEJ, allogeneic fibroblast cell
therapy may be useful. From a practical perspective, injection
of cell volumes of 40.25ml per cm2 to any one site can be
painful, and appropriate analgesia (topical or systemic) may
be necessary if multiple injections are anticipated. For
patients with more generalized disease, associated with
extensive scarring and contractures and with the absence of
type VII collagen protein at the DEJ, alternative cell therapy
or other strategic approaches may be more effective.
Bone marrow stem cell therapy for RDEB
Cell-based therapy for heritable skin diseases has recently
been extended to include bone marrow–derived adult stem
cells (BMDCs). These cells are known to have a crucial role
in skin homeostasis; however, it has become clear that the
plasticity of BMDCs also enables their differentiation into cell
types responsible for skin regeneration after injury. Chronic
wounding, such as in EB, has been shown to stimulate the
engraftment of BMDCs to the skin and their incorporation
and differentiation into nonhematopoietic skin structures
(Badiavas and Falanga, 2003; Badiavas et al., 2003; Tamai
et al., 2011).
A number of studies in mice have been conducted to
evaluate the potential of BMDCs to treat RDEB. For example,
bone marrow transfer into the fetal circulation of Col7a1/
mice resulted in the deposition of type VII collagen around
developing hair follicles, reduction in the severity of
blistering in neonatal animals, and extension of the overall
lifespan of mutant mice (Chino et al., 2008). In another study,
hematopoietic and nonhematopoietic populations were
infused into unconditioned Col7a1/ mice at birth or soon
thereafter (Tolar et al., 2009). Strikingly, 3 of 13 (23%)
recipient mice of adult bone marrow survived for several
months, with evidence of skin engraftment of donor cells,
production of type VII collagen in the skin, and formation of
Col7a1-positive anchoring fibrils (Tolar et al., 2009). In
addition, a model of milder junctional EB—the Col17a1/
mouse—was used to test the skin differentiation capacity of
various bone marrow–derived subpopulations of cells (Fujita
et al., 2010). These studies demonstrated that both purified
hematopoietic stem cells and cultured mesenchymal stem
cells ameliorated clinical symptoms and improved survival
rates (Tolar et al., 2009; Fujita et al., 2010; Tamai et al.,
2011). These findings established the fact that adoptive
transfer of type VII collagen–producing bone marrow cell
populations is sufficient for the partial correction of basement
membrane zone defects in Col7a1/ murine recipients.
Collectively, these preclinical studies provide evidence for
the potential of BMDCs as a source of regeneration of
damaged skin in genetic skin diseases.
The first clinical trial of allogeneic whole bone marrow
was recently reported for seven children with RDEB (Wagner
et al., 2010). New type VII collagen was noted at the DEJ, and
clinical improvement was sustained for at least 1 year after
bone marrow transplantation. Although these results are
promising, two of the seven children died because of
complications in the procedure, which used traditional
chemoablative preconditioning of recipients. A second
clinical bone marrow transplantation trial has been initiated,
using reduced intensity chemotherapy before transplantation
(Kiuru et al., 2010). In addition to bone marrow transplanta-
tion, a pilot study on two patients with severe RDEB
suggested that intradermal injection of allogeneic mesench-
ymal stem cells into chronic ulcerated sites can accelerate
reepithelialization of these wounds (Conget et al., 2010). The
improved wound healing, which lasted for 4 months, was
attributed to replenishment of type VII collagen, which was
undetectable before the procedure. Other studies are now
examining whether intradermal or intravenous injection of
bone marrow–derived mesenchymal stem cells from the same
donor as the transplanted cells in bone marrow transplanta-
tion improves clinical outcome. These early observations
support the usefulness of bone marrow stem cell populations
in correcting basement membrane defects in heritable skin
diseases, such as RDEB (Petrova et al., 2010).
INDUCED PLURIPOTENT STEM CELL THERAPY
The generation of iPSCs from human fibroblasts was first
reported in 2007 (Takahashi et al., 2007; Yu et al., 2007) in
studies demonstrating that exogenous expression of a limited
number of transcription factors was sufficient to reprogram
somatic cells into an embryonic stem cell–like state. iPSCs
express embryonic stem cell markers, have unlimited
proliferative capacity, and can differentiate into all three
germ layers, thus harnessing the full therapeutic spectrum
attributed to embryonic stem cells. Previous stem cell–based
therapies were of limited success because of the difficulty in
obtaining sufficient numbers of undifferentiated cells (adult
stem cells, including BMDCs) and because of the problem of
immune rejection (embryonic stem cells). With characteriza-
tion of iPSCs, regenerative medicine was provided with a
new method to circumvent these obstacles and obtain a
renewable source of immunocompatible, patient-specific
cells. In recent years, patient-specific iPSCs (PS-iPSCs) have
been generated from several human diseases to investigate
disease mechanisms, test potential drugs, and, especially,
develop cell-based therapies. A proof of concept for iPSC-
based therapy was previously provided in a study in which a
sickle-cell anemia mouse model was treated successfully
with hematopoietic stem cells differentiated from gene-
corrected iPSCs that were derived from autologous mouse
skin (Hanna et al., 2007).
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In the field of heritable skin disorders, PS-iPSCs have
recently been generated from patients with dyskeratosis
congenita (Agarwal et al., 2010) and RDEB (Tolar et al.,
2010; Itoh et al., 2011; Uitto, 2011b) (Figure 2). However, to
move iPSC-based therapy to the clinic, several technical
challenges must be overcome. To begin, integration factor–-
free iPSCs must be generated, because integration of viral
transgenes carrying oncogenes, such as MYC and KLF4, into
the genomic DNA of iPSCs may lead to their reactivation
in vivo and subsequently to tumor formation (Okita et al.,
2007). However, rapid development in this field has recently
produced several alternative methods, including plasmid-
based derivation (Okita et al., 2008), recombinant proteins
(Kim et al., 2009), integration-free viral vectors (Yu et al.,
2009; Zhou and Freed, 2009), and mRNA (Warren et al.,
2010), to generate integration-free iPSCs. Second, an efficient
way to correct gene defects in PS-iPSCs must be used. Several
methods of correcting gene mutations have been developed,
with the most promising approach using a type of homo-
logous recombination (HR)–based gene targeting. iPSCs, in
contrast to other somatic cells, are suitable for HR-based gene
correction because of their unlimited, karyotypically stable
proliferation. The first report of gene correction in PS-iPSCs
from a patient with gyrate atrophy was recently published
(Howden et al., 2011), providing a proof of concept for this
technique. However, the low frequency of HR in mammalian
cells still prevents gene targeting from being applied in a
broader therapeutic context. However, recent advances in
generating customized zinc-finger nucleases have paved the
way for HR-based therapeutic strategies (Cathomen and
Joung, 2008). These artificial nucleases can increase the
likelihood of HR at the mutation site up to 10,000-fold. This
technology has been applied successfully to iPSCs, providing
a more efficient strategy for gene targeting as compared with
conventional techniques (Hockemeyer et al., 2009; Zou
et al., 2009).
Another option for mutation-free iPSC derivation from
patients with skin disorders takes advantage of natural gene
therapy in the form of revertant mosaicism. This is a
phenomenon wherein a subpopulation of cells re-acquires
the wild-type phenotype through a naturally occurring
second-site mutation or gene crossover/conversion (Lai-
Cheong et al., 2011). Revertant mosaicism has been observed
in several human genetic disorders (Klein et al., 1992; Wada
et al., 2004), including several types of EB (Jonkman et al.,
1997; Lai-Cheong et al., 2011). As revertant skin in the case
of EB is both visible and easy to obtain via skin biopsy, it may
serve as a natural, patient-specific source of gene-corrected
cells. Taken together, these observations suggest that genera-
tion of gene-corrected PS-iPSCs can be achieved, enabling
development of gene-targeted stem cell–based therapies for
inherited human diseases.
A recent study demonstrated another possible challenge
with iPSCs related to their immunogenicity (Zhao et al.,
2011a). It was shown that autologous mouse iPSC–derived
teratomas were immune rejected in syngeneic recipient mice
with T-cell infiltration. Although this study only suggested
that tumor immunity, and not transplantation immunity, may
be induced by undifferentiated iPSCs, elimination of the other
populations from differentiated cell pools should be achieved
for future clinical use of iPSCs. We recently demonstrated
that both normal iPSCs and RDEB PS-iPSCs can be
differentiated directly into functional keratinocytes, which
constitute one of the relevant cell types for EB treatment (Itoh
et al., 2011). Moreover, keratinocyte-specific surface markers
have been used to purify iPSC-derived keratinocytes (Itoh
et al., 2011), allowing for enrichment of keratinocyte lineage
cells. In summary, iPSCs hold great promise to provide
unlimited and autologous sources of cells for heritable skin
diseases.
NOVEL THERAPEUTICS FOR KERATIN DISORDERS
The past two decades have seen substantial progress in
unraveling the molecular basis of keratinizing skin disor-
ders—a large heterogeneous group of genodermatoses
characterized by fragility and/or overproliferation of epithe-
lial tissues, typically affecting various regions of the epidermis
and its appendages (Irvine and McLean, 1999; McLean and
Irvine, 2007). The keratinopathies—disorders caused by
mutations in genes encoding keratin intermediate filament
proteins—are a good example of such conditions affecting
epidermis, and mutations in 23 of the 54 human keratin
genes have now been linked to human disorders (Omary
et al., 2004). The archetypal keratin disease is epidermolysis
bullosa simplex (EBS), which is caused by mutations in either
of the genes encoding the basal keratinocyte–specific keratins
K5 or K14 (Bonifas et al., 1991; Coulombe et al., 1991; Lane
et al., 1992). Heterozygous missense or in-frame insertion/
deletion mutations in K5 or K14 act via dominant-negative
interference to weaken the structural integrity of the inter-
mediate filament cytoskeleton within the basal cell compart-
ment of the epidermis. Functionally, this cytoplasmic
Somatic cell
(fibroblast)
(cMYC, SOX2,
OCT4, KLF4) iPS cell
Differentiation to
keratinocytes
Assembly of
epidermis Epidermis
BMZ
Dermis
(RA, BMP4)
Reprogramming with
transcription factors
Figure 2. Schematic steps of reprogramming somatic cells, such as fibroblasts, to induced pluripotent stem (iPS) cells and their differentiation into
epidermal keratinocytes capable of forming skin-like structures. The reprogramming process is initiated by introduction of transcription factors
(cMYC, SOX2, OCT4, and KLF4) into somatic cells by transduction of expression vectors, synthetic mRNA, or recombinant protein. The iPS cells have
characteristic features that allow their identification and enrichment. The iPS cells can then be differentiated into keratinocytes under specific culture conditions,
e.g., medium supplemented with retinoic acid (RA) and bone morphogenic protein-4 (BMP-4). BMZ, basement membrane zone. (Adapted from Uitto, 2011b).
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filament network is responsible for maintaining the structural
integrity of basal cells when exposed to high levels of
mechanical trauma experienced by skin in everyday life.
Thus, failure of this system leads to skin blistering confined to
the basal layer of the epidermis, resulting in the clinical and
histopathological hallmarks of EBS (Irvine and McLean,
1999).
Most keratin mutations act through a dominant-negative
pathomechanism because of the highly polymeric nature of
the keratin cytoskeleton, whereby the mutant keratin mono-
mers interact with normal keratin to destabilize the entire
keratin network within the cell. The great challenge in
developing therapy for the common, dominantly inherited,
forms of EBS and most other autosomal dominant keratino-
pathies lies in inhibition of expression of the mutant allele
without silencing the wild-type allele. The proof of concept
for allele-specific gene silencing therapy comes from the
study of unusual EBS families, in which homozygous loss-of-
expression (typically nonsense or frameshift) mutations in
K14 lead to recessively inherited EBS. In these kindreds, the
affected individuals have complete absence of K14 in their
basal keratinocytes, leading to cell fragility via a recessive,
loss-of-function pathomechanism (Rugg et al., 1994). Inter-
estingly, the heterozygous carriers of these loss-of-function
mutations, who only express one K14 allele, have clinically
normal skin. Thus, if a means of silencing a dominant-
negative mutant keratin allele could be found, these data
strongly suggest that such a therapeutic approach would be
likely to succeed (Kaspar, 2005; Lewin et al., 2005).
RNA interference technology
Great strides toward therapy for keratin disorders have been
made in recent years by the application of RNA interference
technology, in the form of small interfering RNA (siRNA), to
address the problem of allele-specific inhibition (Bumcrot
et al., 2006). siRNAs are 19-mer double-stranded RNA
molecules with two-nucleotide overhangs at either end,
which are a perfect match for the mRNA that is to be
silenced. Within the cell, these molecules are incorporated
into the RNA-induced silencing complex, wherein the
antisense strand is used to scan the mRNA species. When
an exact match is found, endonuclease components of RNA-
induced silencing complex degrade the target message. For a
given point mutation, there are 19 possible positions at which
19-mer siRNA can be positioned relative to the single mutant
base. Reporter gene systems, combined with a sequence walk
methodology, facilitate the systemic determination of both
potency and specificity of each of the 19 possible siRNAs to
identify positions at which the mutant reporter gene is strongly
inhibited with minimal or negligible effect on the wild-type
reporter. This methodology has been applied successfully to
specific point mutations in keratin K6a causing pachyonychia
congenita (PC) (Hickerson et al., 2008) and EBS-causing
mutations in K5 (Atkinson et al., 2011).
PC is a rare genetic skin disorder that can be caused by
dominant mutations in any one of the genes encoding
keratins K6a, K6b, K6c, K16, or K17 (McLean et al., 2011).
These keratins are strongly expressed in the palmoplantar
epidermis (Swensson et al., 1998), and therefore a major
clinical feature of PC is painful and highly debilitating focal
keratoderma, particularly affecting the soles of the feet
(McLean et al., 2011). The PC patient advocacy organization
PC Project (www.pcproject.org) has been a key driving force
in the development and implementation of siRNA therapy for
this condition, in close collaboration with an international
network of researchers and a small biotech startup company,
Transderm. This work has recently led to a first-in-human
double-blinded phase 1b clinical trial in which a siRNA
specific for the missense mutation N171K in the K6a protein
was targeted (Leachman et al., 2009). The therapeutic siRNA
was delivered into hyperkeratotic plantar lesions by means of
intradermal injection, which was both painful and highly
inefficient. Nevertheless, significant clinical improvement
was seen in the lesion that received the siRNA, whereas no
difference was observed in the lesion that received vehicle
only. This study provides proof of concept for allele-specific
siRNA therapy for dominant-negative skin diseases; however,
an efficacious and noninvasive delivery method still needs
Wild type Mutant
Mutant allele-
specific siRNA
Mutant and wild type
allele siRNA
DNA
RNA
Protein
Blister
a b c d
Figure 3. Small interfering RNA (siRNA) strategies for autosomal dominant keratin 6a disorders by targeting either mutant or both mutant and wild-type
alleles. (a) In normal keratinocytes, synthesis of K6a (blue), K6b (red), and K6c (green) occurs; (b) in pachyonychia congenita (PC) keratinocytes with a
heterozygous missense mutation in KRT6A, there is a dominant-negative interference between the wild-type and mutant K6a protein that perturbs the entire
keratin network and compromises cell integrity, leading to skin blistering as a result of minor trauma. (c) One siRNA approach is to target the mutant KRT6A
allele to leave only residual wild-type KRT6A allele expression; (d) an alternative siRNA strategy is to silence all KRT6A, both mutant and wild type—blistering
does not occur in the absence of K6a because of functional redundancy with K6b and K6c, allowing normal intermediate filament network integrity.
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to be developed (Figure 3). Cutaneous siRNA delivery is
currently the focus of much attention in the keratin and RNA
interference fields where a number of potential delivery
systems are being explored, including chemical modification
of the siRNA, topical formulation chemistry, nanoparticle
technology, and physical methods such as microneedle arrays.
One disadvantage of the allele-specific gene silencing
approach is that the FDA (Food and Drug Administration) and
related agencies internationally may consider each mutation-
specific siRNA as a separate entity requiring individual
toxicological studies and regulatory approval. With this in
mind, an alternative approach for the treatment of certain
keratin disorders, notably in the keratodermas such as PC, is a
gene-specific approach in which both wild-type and mutant
alleles of the target gene are silenced. In palmoplantar
epidermis in particular, there is significant keratin gene
redundancy. For example, humans possess three versions of
the KRT6 gene—encoding K6a, K6b, and K6c—all of which
are expressed in thick skin. The mouse genome has orthologs
for only K6a and K6b. Single knock out of either of these
murine genes produces a negligible phenotype (Wong et al.,
2000; Wojcik et al., 2001). Only when both K6a and K6b
encoding genes are ablated is an epithelial fragility pheno-
type produced. This shows that there is considerable gene
redundancy in certain epithelial tissues, such as palmoplantar
epidermis. To this end, highly potent gene-specific siRNAs for
human K6 genes have been developed and may be the
weapon of choice in future clinical trials in PC (Smith et al.,
2008). In particular, most PC patients carry mutations in the
K6a gene (Wilson et al., 2011), and therefore most could be
treated with a single K6a-specific inhibitor (Smith et al.,
2008) (Figure 3).
Small-molecule library screen
With the increasing availability of chemical compound libraries
and falling costs of robotic liquid-handling technologies, recent
years have seen considerable developments in academic drug
discovery, which was previously solely within the domain of
the pharmaceutical industry (Kozikowski et al., 2006). Accord-
ingly, increasing numbers of drugs entering clinical use have
their origins in academic laboratories. In addition, this
technology has been applied to PC, in which small molecules
that reduce the expression of PC-related keratins, such as K6a,
have been sought through high-throughput screening using
cell-based reporter gene assay systems. This has led to the
discovery that statins, drugs in common use for cholesterol
control, have a modest inhibitory effect on K6a and certain
other keratins (Zhao et al., 2011b). This work has led to
ongoing clinical trials in a well-studied and genetically
confirmed PC case series, coordinated by the International PC
Research Consortium. Although this type of therapy may not be
curative, it may help alleviate symptoms until more potent and
specific gene silencing therapies enter the clinic.
Overall, the development of therapies from basic dis-
coveries in genetics has been slow, and gene therapy has
been disappointingly slow to enter common clinical applica-
tion. However, with the advent of RNA interference,
academic drug discovery, and greater industry–academia
partnerships (Vallance et al., 2010), the landscape is
changing rapidly, giving hope for patients with devastating
inherited skin disorders.
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